MedTrace Logo

Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension

NCT02782026 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 273

Last updated 2021-05-04

No results posted yet for this study

Summary

In this prospective case-control study, the investigators will evaluate the diagnostic performance of a novel electronic nose (E-nose) for the detection of Pulmonary Arterial Hypertension (PAH). This study is designed to:

1. Assess the performance of the E-nose to discriminate controls from patients with PAH
2. Assess the performance of the E-nose to discriminate between different subtypes of pulmonary hypertension (PH), namely idiopathic PAH, heritable PAH with BMPR2 mutation and chronic thromboembolic PH
3. Assess the performance of the E-nose to discriminate controls from asymptomatic patients with PH who carry BMPR2 mutations.

Conditions

  • Pulmonary Hypertension

Interventions

DEVICE

Exhaled Breath Olfactory Signature (Artificial Nose)

Sponsors & Collaborators

  • Technion, Israel Institute of Technology

    collaborator OTHER

  • Bayer

    collaborator INDUSTRY

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Marc Humbert, MD,PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-04
Primary Completion
2018-08-28
Completion
2018-09-04

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02782026 on ClinicalTrials.gov